Holen Sie sich die Stockscreener-App
206.57
2.32%
-4.91
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten
How a broad sell-off rattled top 3% breakout stock Ligand Pharma - MSN
LIGAND PHARMACEUTICALS INCORPORATED (LGND) - MSN
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Is It Too Late To Consider Ligand Pharmaceuticals (LGND) After A 105% One-Year Surge? - simplywall.st
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Up 6.9%What's Next? - MarketBeat
Ligand Pharmaceuticals Is A Low-Risk Way To Bet On Biopharma Growth: Analyst - Benzinga
Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says - Yahoo! Finance Canada
BofA Securities Initiates Ligand Pharmaceuticals at Buy With $244 Price Target - marketscreener.com
Bofa Global Research announced that it has initiated coverage of Ligand Pharmaceuticals Inc. for the first time, assigning it a "Buy" rating. - Bitget
Ligand stock gains new Buy from BofA (LGND:NASDAQ) - Seeking Alpha
Ligand Pharmaceuticals (LCTX) raises ATM ceiling to $60M with B. Riley - Stock Titan
LGND: B of A Securities Initiates Coverage with Buy Rating and $244 PT | LGND Stock News - GuruFocus
Ligand Pharmaceuticals (NASDAQ:LGND) Now Covered by Analysts at Bank of America - MarketBeat
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Ligand Pharmaceuticals stock hits 52-week high at $213.02 By Investing.com - Investing.com Canada
Ligand Pharmaceuticals (NASDAQ:LGND) Sets New 1-Year HighStill a Buy? - MarketBeat
How The Ligand Pharmaceuticals (LGND) Story Is Shifting Around QTORIN And Royalty Growth - Yahoo Finance
Ligand Pharmaceuticals (NASDAQ:LGND) Rating Lowered to Hold at Wall Street Zen - MarketBeat
Ligand Pharmaceuticals CLO Reardon sells $1m in shares - Investing.com
Ligand Pharmaceuticals (NASDAQ:LGND) CFO Sells $2,762,856.09 in Stock - MarketBeat
Andrew Reardon Sells 5,000 Shares of Ligand Pharmaceuticals (NASDAQ:LGND) Stock - MarketBeat
Ligand Pharmaceuticals director Sabba sells $409k in shares - Investing.com
Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells $409,851.00 in Stock - MarketBeat
Ligand Pharmaceuticals director Sabba sells $409k in shares By Investing.com - Investing.com Canada
Citigroup Inc. Trims Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals director sells $93k in stock - Investing.com India
Ligand Pharmaceuticals director sells $93k in stock By Investing.com - Investing.com Nigeria
Insider Sell: John Kozarich Sells Shares of Ligand Pharmaceutica - GuruFocus
Ligand Pharma (LGND) Earnings Call Transcript - AOL.com
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells 467 Shares of Stock - MarketBeat
Ligand Pharmaceuticals (LGND) Is Up 8.1% After Swinging to Profit and Filing New Equity ShelfWhat's Changed - simplywall.st
[144] LIGAND PHARMACEUTICALS INC SEC Filing - Stock Titan
Ligand to Participate in March Investor Conferences - The Manila Times
Ligand plans three March investor appearances in Miami, Dana Point, NYC - Stock Titan
Ligand Pharmaceuticals (LGND): Investor Outlook With 20.74% Potential Upside - DirectorsTalk Interviews
LGND: 2025 Results & Focus on Qtorin - Yahoo Finance
Ligand Pharmaceuticals (LGND) Is Up 7.8% After Swing to Profit and New ATM Offering Filed – Has The Bull Case Changed? - Yahoo Finance
Expert Outlook: Ligand Pharmaceuticals Through The Eyes Of 5 Analysts - Sahm
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com
LGND Should I Buy - Intellectia AI
Decoding Ligand Pharmaceuticals Inc (LGND): A Strategic SWOT Ins - GuruFocus
Oppenheimer Raises Price Target for LGND, Maintains Outperform R - GuruFocus
Ligand Pharmaceuticals Files For Mixed Shelf Offering - TradingView
Ligand Pharmaceuticals (NASDAQ: LGND) files S-3 for $100M ATM offering with Leerink - Stock Titan
LIGAND PHARMACEUTICALS INC SEC 10-K Report - TradingView
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Expected to Rise, Oppenheimer Analyst Says - MarketBeat
Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $277 From $275, Maintains Outperform Rating - marketscreener.com
Vanguard Group Inc. Has $367.79 Million Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Assessing Ligand Pharmaceuticals (LGND) Valuation After Strong One Year Returns And Elevated P/E Ratio - simplywall.st
Oppenheimer raises Ligand Pharma stock price target on royalty outlook By Investing.com - Investing.com Canada
Ligand Pharmaceuticals (NASDAQ:LGND) Announces Quarterly Earnings Results, Beats Expectations By $0.56 EPS - MarketBeat
Ligand Pharmaceuticals Incorporated (LGND) Q4 2025 Earnings Call Transcript Summary - 富途牛牛
Stifel reiterates Buy on Ligand Pharma stock, keeps $230 target - Investing.com Nigeria
Ligand Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Stifel reiterates Buy on Ligand Pharma stock, keeps $230 target By Investing.com - Investing.com Canada
Ligand Pharmaceuticals Inc (LGND) Q4 2025 Earnings Call Highligh - GuruFocus
Ligand Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Operating cash flow per share of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
Ligand Pharmaceuticals Incorporated Reiterates Earnings Guidance for the Year 2026 - marketscreener.com
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):